Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Summary

The rationale for this study is to provide additional treatment with NEOD001 for subjects who complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability. All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be continued in this study.

Timeline

Start

2016-02

Primary completion

2018-05

Completion

2018-05

Drugs

Indications